CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,146 enrolled
Drug / intervention
PegIntron (peginterferon alfa-2b; SCH 54031) +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00724854
NCT00724854N/ACompleted
CompareCT.gov

Evaluation of Rapid Virological Response in HCV Patients Treated With PegIntron and Ribavirin - APEGIN Trial

Merck Sharp & Dohme LLC·observational·Posted Jul 30, 2008·Updated Feb 25, 2015

In Brief

An observational study evaluating PegIntron (peginterferon alfa-2b; SCH 54031) and Rebetol (ribavirin; SCH 18908) for Hepatitis C, Chronic and Hepatitis C. Completed, enrolled 1,146 participants.

Detailed Summary

The objective of the study is to evaluate, in each group, the number of participants who achieve rapid virological response (RVR) after 4 weeks treatment with PegIntron and Rebetol. The study will also assess whether RVR is a reliable predictor of sustained virologic response (defined as undetectable viral load at 24 weeks post-treatment).

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C, Chronic, Hepatitis C
Countries--
Collaborators--

Timeline

N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 30, 2008
Enrollment StartAug 1, 2006
Primary CompletionSep 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 17.9 years ago

Interventions

PegIntron (peginterferon alfa-2b; SCH 54031)biological

PegIntron administered in accordance with approved labeling

Rebetol (ribavirin; SCH 18908)drug

Rebetol administered in accordance with approved labeling